Gilead Sciences’ closely-watched COVID-19 drug candidate remdesivir outperformed placebo in a clinical trial sponsored by the NIH’s National Institute of Allergy and Infectious Disease (NIAID), the agency announced today—the first clinical study launched in the U.S. of a therapeutic for the virus.
NIAID released preliminary data showing that the study met its primary outcome of statistically significant improvement in time to recovery by Day 29. Patients who were treated with remdesivir showed a median time to recovery of 11 days compared with 15 days for those who received placebo—a 31% faster time to recovery.
{iframe}https://www.genengnews.com/news/niaid-gileads-remdesivir-shows-positive-proof-of-concept-in-hospitalized-covid-19-patients/?utm_medium=newsletter&utm_source=GEN+Daily+News+Highlights&utm_content=01&utm_campaign=GEN+Daily+News+Highlights_20200430&oly_enc_id=8564G0015734H2C{/iframe}